Chhikara Sunita, Sazawal Sudha, Mishra Pravas, Chaubey Rekha, Mahapatra Manoranjan, Saxena Renu
Department of Haematology, All India Institute of Medical Sciences, New Delhi 110029, India.
Department of Haematology, All India Institute of Medical Sciences, New Delhi 110029, India,
Natl Med J India. 2015 Nov-Dec;28(6):272-5.
Patients with chronic myeloid leukaemia show an excellent response to treatment with imatinib. However, in some patients, the disease is resistant to imatinib. This resistance may be related to the presence of genetic variations on the drug's pharmacokinetics and metabolism. We therefore studied three polymorphisms (C1236T, G2677T and C3435T) in the human multidrug-resistance gene (MDR1) in 86 patients with chronic myeloid leukaemia treated with imatinib. Imatinib resistance was more frequent in patients with TT genotype at locus 1236 than in those with CT/CC genotypes (p=0.003). For the other two loci (G2677T and C3435T), resistance was seen to be higher for TT genotype when compared to GG/GT and CT/CC but it was not statistically significant (p=0.13 and p=0.099). In conclusion, determination of C1236T MDR1 genotype may help to predict response to imatinib therapy in patients with chronic myeloid leukaemia.
慢性髓性白血病患者对伊马替尼治疗显示出良好的反应。然而，在一些患者中，该疾病对伊马替尼耐药。这种耐药性可能与药物的药代动力学和代谢方面的基因变异有关。因此，我们研究了86例接受伊马替尼治疗的慢性髓性白血病患者的人类多药耐药基因（MDR1）中的三种多态性（C1236T、G2677T和C3435T）。1236位点TT基因型的患者比CT/CC基因型的患者伊马替尼耐药更常见（p = 0.003）。对于其他两个位点（G2677T和C3435T），与GG/GT和CT/CC相比，TT基因型的耐药性更高，但无统计学意义（p = 0.13和p = 0.099）。总之，测定C1236T MDR1基因型可能有助于预测慢性髓性白血病患者对伊马替尼治疗的反应。
